Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Performance of the ELN 2022 risk stratification in a real-world Canadian AML patient population

View Full Paper
Ask AI
Bookmark
Share

Authors

EZEric J. ZhaoFKFlorian KuchenbauerYMYasser Abou Mourad

Discussion

Loading...

Member takes

Overview

Analysis reveals risk stratification impacts overall survival in AML patients, highlighting mutation effects and stem cell transplant outcomes.

Key Points

  • To assess the performance of the ELN 2022 risk stratification in a real-world AML cohort.
  • Analyzed 499 AML patients in British Columbia
  • Evaluated overall survival based on ELN 2022 classifications
  • Compared outcomes by risk categories including complete remission and stem cell transplant rates
  • Median overall survival differed significantly among risk groups: favorable (75 months), intermediate (30 months), and adverse (27 months)
  • 85.7% of favorable-risk patients achieved complete remission after one cycle of therapy
  • A high proportion of patients underwent stem cell transplant, which may affect outcomes.

Cite This Study

Zhao et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9eahttps://doi.org/10.1182/blood-2025-5178
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Risk stratification of newly diagnosed AML receiving nonintensive treatment2025
  2. 2TP53, EZH2, or RUNX1 mutations predict poor outcomes in ELN 2022 adverse risk group of adult AML patients undergoing allo-HSCT2025
  3. 3Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group2024 · 8 citations
  4. 4Treatment-specific prognostic performance of ELN 2022, ELN 2024, and beat AML 2024: A real-world AML validation study2025
  5. 5Prognostic Impact of European LeukemiaNet Genetic Risk Stratification System in Adult Patients With Acute Myeloid Leukemia2026 · 1 citations